#151
|
||||
|
||||
Ðàáîòà èç Êàíàäû î ïðåäàíåìè÷åñêîì äåôèöèòå æåëåçà ó äåòåé: ÷àñòîòà, ôàêòîðû ðèñêà, êàê ÷àñòî êîððåêòèðóåòñÿ âðà÷àìè è êàêîâ ðåçóëüòàò:
Of 2276 children undergoing screening, 155 had Of 2276 children undergoing screening, 155 had non-anemic iron deficiency (NAID), corresponding to a prevalence of 7% (95% CI 5.95% to 8.05%). Risk factors significantly associated with NAID included: younger age (OR 1.08 [95% CI 1.06 to 1.11]), higher body mass index z-score (OR 1.22 [95% CI 1.01 to 1.48]), longer duration of breastfeeding (OR 1.05 [95% CI 1.01 to 1.08]) and increased volume of cow's milk intake (OR 1.13 [95% CI 1.01 to 1.26]). An assessment of practice patterns revealed that for 37% of children, an intervention for NAID was documented; and for 8.4% a physician-ordered follow-up laboratory test was completed to re-evaluate iron status. A total of 58 (37%) children underwent a follow-up laboratory test, of whom 38 (65.5%) had resolution of NAID, 15 (25.9%) had persistence of NAID and two (3.4%) had progression of NAID to anemia. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#152
|
||||
|
||||
Äîêëàä AAP ïî ìëàäåí÷åñêèì ãåìàíãèîìàì
Îïóáëèêîâàí äîêëàä Àìåðèêàíñêîé àêàäåìèè ïåäèàòðèè ïî ìëàäåí÷åñêèì ãåìàíãèîìàì. Ïåðâûé â ñâîåì ðîäå. Ýòî íå ãàéäëàéí, ýòî ÷èñòî îáó÷àþùåå ðóêîâîäñòâî, ñóììèðóþùåå ïîñëåäíèå íàó÷íûå äàííûå ïî ýòîé ïðîáëåìå.
Äîêëàä êðàñî÷íî è îáèëüíî èëëþñòðèðîâàí ôîòîãðàôèÿìè. Ïðèãîäèòñÿ êàê ïåäèàòðàì, òàê è âðà÷àì äðóãèõ ñïåöèàëüíîñòåé, èìåþùèì äåëî ñ ìëàäåí÷åñêèìè ãåìàíãèîìàìè. Íîâîñòü: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Ïîëíîòåêñò: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Òîëüêî ïîìíèòå: ôîðóì - íå çàìåíà î÷íîìó âðà÷ó, à ëå÷åíèå ïî èíòåðíåòó - ÷ðåâàòî ñìåðòüþ îò îïå÷àòêè. Ñ óâàæåíèåì, Ñåðãåé Àëåêñàíäðîâè÷. |
#153
|
||||
|
||||
Èçáûòîê êîðîâüåãî ìîëîêà â ðàöèîíå äåòåé 1-3 ëåò èç Åâðîïû àññîöèèðóåòñÿ ñ ðèñêîì êàê äåôèöèòà æåëåçà, òàê è äåôèöèòîì âèòàìèíà Ä, êîè âñòðå÷àþòñÿ â ýòîì âîçðàñòå ñ ÷àñòîòîé 12% è 23% ñîîòâåòñòâåííî:
In 325 children (Caucasian race 95%; male 56%; mean age 20.7 months) the overall prevalence of ID and VDD was 11.8% and 22.8%, respectively. The use of primarily cow's milk as major type of milk was associated with ID (OR 3.20, 95% CI 1.12-8.53) and VDD (OR 7.17, 95% CI 3.10-16.57). The use of vitamin D supplements (OR 0.20, 95% CI 0.07-0.56) was associated with a lower prevalence of VDD. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#154
|
||||
|
||||
Íó âîò
ÐÌÑ ìåíÿ íàó÷èë ôîðìóëå "íà ãðóäíîì âñêàðìëèâàíèè íå áûâàåò îæèðåíèÿ", è ÿ ÷àñòî óñïîêàèâàë ýòèì ìàòåðåé. Îäíàêî íîâîå èññëåäîâàíèå îïðîâåðãàåò ýòó òî÷êó çðåíèÿ. Öèòàòà:
Öèòàòà:
Öèòàòà:
Öèòàòà:
__________________
Òîëüêî ïîìíèòå: ôîðóì - íå çàìåíà î÷íîìó âðà÷ó, à ëå÷åíèå ïî èíòåðíåòó - ÷ðåâàòî ñìåðòüþ îò îïå÷àòêè. Ñ óâàæåíèåì, Ñåðãåé Àëåêñàíäðîâè÷. |
#155
|
|||
|
|||
À â ÷åì òîãäà çàêëþ÷àåòñÿ ïðîôèëàêòèêà îæèðåíèÿ íà ÃÂ?
Êîðìèòü ïî ÷àñàì? Ïîèòü âîäîé âìåñòî ìîëîêà? Ðàçáàâëÿòü ìîëîêî? |
#156
|
||||
|
||||
Äûê òî ïîäè ó àìåðèêàíñêèõ ëþäåé òàêèå ïðîáëåìû - îíè óæå ïîìåøàëèñü íà îæèðåíèè è åãî ïðîôèëàêòèêå
Exclusive breastfeeding to reduce the risk of childhood overweight and obesity Biological, behavioural and contextual rationale WHO technical staff September 2014 |
#157
|
|||
|
|||
Öèòàòà:
ß äî ñèõ ïîð óìà íå ïðèëîæó, êàê ýòî ïðîôèëàêòèðîâàòü îæèðåíèå íà à(ýòèì âîïðîñîì çàäàâàëñÿ âûøå). Ìîðèòü ãîëîäîì, ÷òîáû îáìàíóòü ãåíû? Õîòÿ ÿ ïðåêðàñíî ïîíèìàþ, ÷òî ñåìåéíîå îæèðåíèå - ýòî çà÷àñòóþ íå óíàñëåäîâàííûé îáìåí âåùåñòâ, à óíàñëåäîâàííûå ïèùåâûå ïðèâû÷êè. Íî âñå æå... |
#158
|
||||
|
||||
Î âàêöèíå Âèòàãåðïàâàê äëÿ äåòåé
Ðûëñÿ ïî òåðàïèè óïîðíîãî ðåöèäèâèðóþùåãî ãóáíîãî ãåðïåñà ó òðåõëåòêè, è íàøåë ïðî ëå÷åáíûå âàêöèíû èíôó.
Äåëþñü Öèòàòà:
Êîãäà ñïåöèàëüíî èñêàë ïî çàïðîñó íà âàêöèíû - íå ìîã íàéò Ñîáñòâåííî íè÷åãî íîâîãî íå óçíàë - äîêàçàòåëüíàÿ áàçà ñëàáàÿ, íî ìîæíî ïîïðîáîâàòü îò îò÷àÿíèÿ èíîãäà. Òàê ìàìå è ñêàçàë.
__________________
Òîëüêî ïîìíèòå: ôîðóì - íå çàìåíà î÷íîìó âðà÷ó, à ëå÷åíèå ïî èíòåðíåòó - ÷ðåâàòî ñìåðòüþ îò îïå÷àòêè. Ñ óâàæåíèåì, Ñåðãåé Àëåêñàíäðîâè÷. |
#159
|
||||
|
||||
Ñòàòüÿ î òîì êàê íå ñïóòàòü child abuse ñ èñòèííûìè êîæíûìè áîëåçíÿìè, êîãäà ïîñëåäíèå î÷åíü ïîõîæè íà ñëåäû íàñèëèÿ
Îñòîðîæíî, ñòàòüÿ ñòðîãî äëÿ âðà÷åé, ôîòîãðàôèè íå äëÿ ñëàáîíåðâíûõ [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Òîëüêî ïîìíèòå: ôîðóì - íå çàìåíà î÷íîìó âðà÷ó, à ëå÷åíèå ïî èíòåðíåòó - ÷ðåâàòî ñìåðòüþ îò îïå÷àòêè. Ñ óâàæåíèåì, Ñåðãåé Àëåêñàíäðîâè÷. |
#160
|
||||
|
||||
Àðáèäîë ñòàë ïëîõî ïðîäàâàòüñÿ, ÷òî ëè. Íà÷àëèñü àãðåññèâíûå ïèàð-êàìïàíèè â ñîöñåòÿõ è ïðîôåññèîíàëüíûõ ìåäèöèíñêèõ ôîðóìàõ. Àâòîðû ñûïÿò ññûëêàìè íà èññëåäîâàíèÿ óìèôåíîâèðà â Ïàáìåäå è íåèñêóøåííûé äîêòîð âïîëíå ìîæåò ðàñòåðÿòüñÿ è çàïóòàòüñÿ (íàïðèìåð, ìåíÿ îñåíüþ ìåäïðåä ñìóòèëà â äèñêóññèè, ÿ íå äîâåðÿþ àðáèäîëó, íî íå çíàë ÷åì åé îïïîíèðîâàòü).
Ñîâåòóþ êîëëåãàì ïðî÷åñòü ýòî âðà÷åáíîå îáñóæäåíèå, ÷òîáû áûòü çíàêîìûì ñ àðãóìåíòàìè îáåèõ ñòîðîí [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Òîëüêî ïîìíèòå: ôîðóì - íå çàìåíà î÷íîìó âðà÷ó, à ëå÷åíèå ïî èíòåðíåòó - ÷ðåâàòî ñìåðòüþ îò îïå÷àòêè. Ñ óâàæåíèåì, Ñåðãåé Àëåêñàíäðîâè÷. |
#161
|
||||
|
||||
Ñõåìàòè÷íûé êðàòêèé ãàéä ïî êðóïó, ìíå ïîíðàâèëñÿ: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ].
|
#162
|
||||
|
||||
íåîíàòàëüíûé ãåìàíãèîìàòîç
Õîòÿ âñòðå÷àåòñÿ íå ÷àñòî, íî 1-3 ðàçà â ïðàêòèêå âðà÷à ìîæåò âñòðåòèòñÿ. Ðåêîìåíäóþ ñòàòüþ [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Neonatal Hemangiomatosis Ãåìàíãèîìàòîç, îïðåäåëÿåòñÿ êàê êðàòíîå (êàê ïðàâèëî, ïÿòü èëè áîëåå) ãåìàíãèîì, ïðåäñòàâëåí íåáîëüøèìè êîæíûìè ãåìàíãèîìàìè(êðàñíûå ïàïóëû è óçåëêè âàðüèðóþòñÿ â ðàçìåðàõ îò áóëàâî÷íîé ãîëîâêè äî 1 ñì), êîòîðûå ìîãóò âîçíèêíóòü â ëþáîì ìåñòå íà êîæå èëè ñëèçèñòûõ îáîëî÷åê.  äîïîëíåíèå ê êîæíûìè ïîðàæåíèÿìè, hemangiomatosis ìîæåò âêëþ÷àòü âíóòðåííèå îðãàíû, â òîì ÷èñëå, íî íå îãðàíè÷èâàÿñü èìè, ïå÷åíü, æåëóäî÷íî-êèøå÷í.òðàêò è ãîëîâíîé ìîçã. ïðèìèòèâíûé ïåðåáîä äëÿ ëåíèâûõ çäåñü http://forums.rusmedserv.com/showthr...11#post2416911 |
#163
|
||||
|
||||
Êàê è ïî÷åìó ãîìåîïàòèÿ ìîæåò ïðîâîäèòü ê âîçíèêíîâåíèþ ïîá. ýôôåêòîâ è äàæå ñìåðòè ìàëåíüêèõ äåòåé - â ïîñëåäíåì íîìåðå æóðíàëà
Amid Reports of Infant Deaths, FTC Cracks Down on Homeopathy While FDA Investigates [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#164
|
||||
|
||||
Âèäåîïðåçåíòàöèÿ Áóòðèÿ ÑÀ î òàêòèêå ïðîâåäåíèÿ äîãîíÿþùåé âàêöèíàöèè ó äåòåé
Âîçìîæíî êîëëåãàì áóäåò èíòåðåñíà ìîÿ âèäåîïðåçåíòàöèÿ
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Òîëüêî ïîìíèòå: ôîðóì - íå çàìåíà î÷íîìó âðà÷ó, à ëå÷åíèå ïî èíòåðíåòó - ÷ðåâàòî ñìåðòüþ îò îïå÷àòêè. Ñ óâàæåíèåì, Ñåðãåé Àëåêñàíäðîâè÷. |
#165
|
||||
|
||||
Äâå íåäàâíèå ïóáëèêàöèè èç Èçðàèëÿ î ïîâûøåííîì ðèñêå îïóõîëåé ó äåòåé, çà÷àòûõ ïðè èñïîëüçîâàíèè âñïîìîãàòåëüíûõ òåõíîëîãèé (ÝÊÎ è òï.):
Pediatr Blood Cancer. 2017 Apr;64(4). Possible risk for cancer among children born following assisted reproductive technology in Israel. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Am J Obstet Gynecol. 2017 Mar;216(3):314.e1-314.e14. Fertility treatments and pediatric neoplasms of the offspring: results of a population-based cohort with a median follow-up of 10 years. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |